Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors

Medical University of Vienna

Status and phase: Unknown; Phase 4

Conditions: Ssri; Neuronal Plasticity

Treatments: Other: 3xMR scan (fMRI, DTI, strucutral MRI); Behavioral: Association re-learning paradigm; Behavioral: Association learning paradigm; Drug: Escitalopram; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02753738

21042016

Details and patient eligibility

About

Background:

Conclusive evidence states that the serotonergic system mediates neuroplasticity from early embryonic development until brain maturation in adulthood. This study aims to demonstrate that selective serotonin reuptake inhibitors (SSRIs) enhance learning-dependent neuroplasticity in vivo, hereby contributing to the investigators understanding of the mechanism of action of therapy with SSRIs.

Objectives:

1. To prove a positive influence of SSRIs on structural remodeling during learning, reflected by enhancements of gray and white matter microstructure, connectivity and functionality in brain regions involved in learning processes.
2. To show that this effect is topologically specific, i.e. that enhancements of plasticity markers are found in different regions depending on their involvement during the performance of specific learning tasks.

Study design:

Randomized, double-blind, placebo-controlled, longitudinal mono-center study. 80 healthy subjects will undergo three MRI scanning sessions: 1. baseline, at study entry, 2. after 3 weeks of facial/emotional (n=40) or Chinese character-meaning learning (n=40) and 3. after 3 weeks learning of new associations under administration of an SSRI or placebo.

Methods:

MRI measurements will be performed on a 3 Tesla PRISMA MAGNETOM MR scanner. Changes in gray matter microstructure will be assessed using high-resolution structural MRI and analyzed with voxel-based morphometry (VBM). Diffusion tensor imaging (DTI) enables non-invasive investigation of neuroplasticity in the human brain based on the reduction in mean diffusivity associated with swelling of astrocytes after increased synaptic activity. Resting-state functional MRI (fMRI) will allow for the measurement of changes in functional coupling between brain regions, and fMRI during tasks will assess differential activity in brain regions during learning.

Relevance and implications:

This study aims to provide evidence that SSRIs facilitate cytoarchitectonical restructuring. In addition to expanding the investigators current knowledge on the trophic effects of SSRIs, the results of this study will also elucidate interactions between the serotonergic system and changes to neuronal networks during learning as well as their behavioral consequences. By probing the neurobiological correlates of the antidepressant and anti-anxiety effects of SSRIs, this study will provide a rationale for targeted interventions that harness the neuroplasticity enhancing properties of SSRIs to facilitate therapeutic processes.

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• General health based on medical history, physical examination and structured clinical interview for DSM-IV (SCID)
• Willingness and competence to sign the informed consent form
• Right-handedness
• Non-smoker, and non-alcohol drinker

Exclusion criteria

• Any medical, psychiatric or neurological illness
• Current or former substance abuse
• Any implant or stainless steel graft or any other contraindications for MRI
• First degree relatives with a history of psychiatric illness or substance abuse
• Color blindness, any Chinese language skills
• Failure to comply with the study protocol or to follow the instructions of the investigating team
• Lifetime use of SSRIs or related psychotropic agents
• Non-Caucasian

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

80 participants in 2 patient groups, including a placebo group

SSRI treatment

Experimental group

Description:

Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.

Treatment:

Drug: Escitalopram

Other: 3xMR scan (fMRI, DTI, strucutral MRI)

Behavioral: Association learning paradigm

Behavioral: Association re-learning paradigm

Placebo treatment

Placebo Comparator group

Description:

Subjects will receive 21 days of placebo treatment while performing learning paradigms.

Treatment:

Other: 3xMR scan (fMRI, DTI, strucutral MRI)

Behavioral: Association learning paradigm

Behavioral: Association re-learning paradigm

Drug: Placebo